Florida / New York

Ph: 561.316.3330

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

Medical Device News Magazine is a digital Publication Founded in 2008, and proudly located in the United States, Medical Device News Magazine has established itself as one of the foremost and most trusted sources of comprehensive updates and insights within the medical device and biotech industries. Our publication is committed to delivering timely and relevant information, making it a go-to resource for professionals and enthusiasts alike.

Medical Device News Magazine is easily accessible to readers 24/7/365, allowing you to stay informed at your convenience, and it presents content that is a fast and engaging read. We take pride in offering valuable insights in a format that can be consumed quickly, ensuring that our audience stays ahead of the curve.

Furthermore, if you are interested in expanding your reach and visibility within this dynamic field, we encourage you to inquire about advertising opportunities with us.

"Medical Device and Biotechnology Sector News: Essential Key Insights and Noteworthy Developments that are Shaping the Future"

Fluidx Unveils New Embolic for Neurovascular Use

Fluidx Unveils New Embolic for Neurovascular Use

The IMPASS Embolic Device is part of the portfolio of embolics currently under development by Fluidx.  In the fall, Fluidx announced successful completion of a multi-center clinical trial with the GPX Embolic Device to treat a broad range of peripheral applications including tumor devascularization.

Innovative Solutions for Today's Challenges, Secured Funding for a Brighter Future

Industry Expert Byline

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

“Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH,” stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. “Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024.”

Comprehensive Insights into Medical Device and Biotechnology Company Mergers and Acquisitions Trends and Strategies

Philips Signs An Agreement to Acquire Capsule Technologies, Inc

“Integrated patient care management solutions supported by essential real-time patient data and AI are core to our strategy to improve patient outcomes and care provider productivity by seamlessly connecting care,” said Roy Jakobs, Chief Business Leader Connected Care at Royal Philips.

FDA Medical Device Updates

Our Experts - Byline Articles

Medical Imaging Technologies and Their Impact on Modern Healthcare

Healing Headlines, Transforming Lives: Hospitals in the News

Medical Device and Biotechnology Executives: Innovative Professionals on the Move and Making Waves in the Industry

Non-Profit News

Executives on the Move

Healthcare - Understanding the Business Side of the Industry and Its Implications

Healthcare Careers and Opportunities in the Evolving Medical Field

Nurses Corner: A Dedicated Space for Professional Insights and Resources

Articles Designed to Inspire and Guide You Toward Achieving Excellence and Success in All Your Endeavors.